PRINCIPLES OF CANCER TREATMENT PPT

Chapter 081. Principles of Cancer Treatment (Part 1) Harrison's Internal Medicine > Chapter 81. Principles of Cancer Treatment Principles of Cancer Treatment: Introduction The goal of cancer [r]

Chapter 081. Principles of Cancer Treatment (Part 23) Mucositis Irritation and inflammation of the mucous membranes particularly afflicting the oral and anal mucosa, but potentially involving the gastrointestinal tract, may accompany cytotoxic chemotherapy. Mucosi[r]

Published: 22 August 2011References1. Guyatt GH, Ferrans CE, Halyard MY, Revicki DA, Symonds TL, Varricchio CG,Kotzeva A, Valderas JM, Alonso J: Exploration of the value of health-related quality-of-life information from clinical research and into clinicalpractice. Mayo Clin Pro[r]

Cancer-related fatigue (CRF) is a common and distressing symptom of cancer and/or cancer treatment that persists for years after treatment completion in approximately one third of cancer survivors.

provoke a host-mediated immune response. Key issues in the success of these approaches will be in defining safe viral vector systems that escape host immune function and effectively target the tumor or tumor cell milieu. Other gene therapy strategies would utilize therapeutic oligonucleotides[r]

Tumors themselves are very poor at presenting their own antigens to T cells at the first antigen exposure (priming). Priming is best accomplished by professional antigen-presenting cells (dendritic cells). Thus, a number of experimental strategies are aimed at priming host T cells against tum[r]

anxiolytic effect to augment the effectiveness of a variety of agents when used at 1–2 mg intramuscularly, intravenously, or orally every 4–6 h. Metoclopramide (Reglan) acts on peripheral dopamine receptors to augment gastric emptying and is used in high doses for highly emetogenic reg[r]

patients with myeloproliferative states may have functionally altered platelets despite normal platelet counts, and transfusion with normal donor platelets should be considered for evidence of bleeding in these patients. Careful review of medication lists to prevent exposure to nonster[r]

Do not use concurrently with chemotherapy or radiation therapy Note: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor. Source: From the American Society of Clinical Oncology.

in a neutropenic patient with an uncontrolled neoplasm involving the bone marrow or, more usually, in a patient undergoing treatment with cytotoxic agents. Mortality from uncontrolled infection varies inversely with the neutrophil count. If the nadir neutrophil count is >1000/µL, there[r]

itself or other genetic lesions. Its side effects are relatively tolerable in most patients and include hepatic dysfunction, diarrhea, and fluid retention. Rarely, patients receiving imatinib have decreased cardiac function, which may persist after discontinuation of the drug. The quality [r]

QOL score. An additional score, the Trial Outcome Index(TOI) [26,27], is created by summing the PWB, FWB, andProstate Cancer Subscale (PCS). Responses to FACT ques-tions use a five-point Likert-type scale ranging from 0("not at all") to 4 ("very much so"). The FACT-G has goodtest-retest relia[r]

Breast cancer treatment is tailored to the specific cancer subtype. Often, systemic treatment is given prior to surgery. Chemotherapy induces significant endoplasmic reticulum (ER) stress-mediated cell death and upregulation of 78-kDa glucose-regulated protein (GRP78).

With the increased prevalence of tumor somatic and patient germline sequencing, our ability to study the re- lationship between genomics and treatment response and survival will grow. A number of prior studies have studied gene mutations in KRAS, CDKN2A, TP53 and SMAD4 with rega[r]

Globally, cancer is one of the leading causes of mortality. High treatment cost, partly owing to higher prices of anti-cancer drugs, presents a significant burden on patients and healthcare systems.

Metastatic breast cancer carries a poor prognosis despite the success of newly targeted therapies. Treatment options remain especially limited for the subtype of triple negative breast cancer (TNBC).

Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the United States and worldwide.

Patients with advanced lung cancer (LC) or malignant pleural mesothelioma (MPM) exhibit limitation of exercise capacities and alteration of quality of life (QoL) induced by cancer and its treatment.

margins and well-differentiated tumors. Despite a dismal long term outcome, these patients still have a better survival with surgery than with other palliative measures. Surgery is usually preceded by laparoscopy in order to exclude peritoneal metastases not seen on other staging investigations. Pan[r]

•  Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharmaceutical Research. 2006; 23(7): 1417-50. •  Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE. Targeted nanoparticles for detecting and treating cancer. Drug Development Research. 2006; 67:[r]